Table 2.
Base case analysis
| Treatment arm | Cost (USD) | QALYs | Increased cost (USD) | Increased QALYs | ICER (USD/QALY) | NMB (USD) | |
|---|---|---|---|---|---|---|---|
| SOC vs. SOC + RT (20 fractions RT) | |||||||
| Only NRLN metastases | SOC | 154,788 | 2.89 | -10,312 | |||
|
SOC + RT (20 fractions) |
180,886 | 3.81 | 26,098 | 0.92 | 28,452 | 9,453 | |
| ≤ 3 bone metastases | SOC | 173,899 | 3.24 | -12,078 | |||
|
SOC + RT (20 fractions) |
327,389 | 7.07 | 153,490 | 3.83 | 40,032 | 26,144 | |
| ≥ 4 bone metastases | SOC | 195,501 | 3.44 | 14,862 | 0.03 | 478,797 | -23,539 |
|
SOC + RT (20 fractions) |
180,639 | 3.41 | -10,230 | ||||
| SOC vs. SOC + RT (6 fractions RT) | |||||||
| Only NRLN metastases | SOC | 154,788 | 2.89 | -10,312 | |||
| SOC + RT (6 fractions) | 176,188 | 3.81 | 21,400 | 0.92 | 23,261 | 14,312 | |
| ≤ 3 bone metastases | SOC | 173,899 | 3.24 | -12,078 | |||
| SOC + RT (6 fractions) | 322,691 | 7.07 | 148,792 | 3.83 | 38,849 | 30,809 | |
| ≥ 4 bone metastases | SOC | 195,501 | 3.44 | 19,559 | 0.03 | 615,967 | -23,539 |
| SOC + RT (6 fractions) | 175,941 | 3.41 | -10,230 | ||||
Results of the cost-effectiveness analysis. For only NRLN metastases SOC + RT was associated with an ICER of USD 28,452 (20 fractions RT) and USD 23,261 (6 fractions RT). For ≤ 3 bone metastases SOC + RT was associated with an ICER of USD 40,032 (20 fractions RT) and USD 38,849 (6 fractions RT). WTP was set to USD 100,000/QALY. The difference in price of the costs of RT with 20 fractions and 6 fractions equals to USD 4,698 for each subgroup.